TOP NEWS
Grief and Rare Disease: Recognizing Loss and Building Grief Literacy
This past May, our hearts broke twice. Within just two weeks, the Pompe community said goodbye to two extraordinary advocates: Maryze Schoneveld van der Linde with the IPA, and our beloved Tiffany House with AMDA/IPA. Their passing illuminated something profound: grief lives everywhere in our community, often in ways we don’t recognize or name.
The parent who mourns the carefree childhood their child will never have. The adult with late-onset Pompe disease who grieves the marathon they’ll never run again. The spouse watching their partner’s strength fade, carrying the weight of tomorrow’s uncertainties. These experiences are real, valid, and profound, yet they often go unacknowledged. We call this grief illiteracy, and it’s time we changed that conversation.
Grief isn’t weakness. It’s love with nowhere to go. It’s hope recalibrating. It’s proof that something mattered deeply to us. When we learn to recognize grief’s many forms and respond with compassion, we create space for authentic healing and build a community where no one has to carry their sorrow alone.
Read the full article to explore the different types of grief, understand how it affects our daily lives, and discover practical ways to build grief literacy in the Pompe community.
OTHER NEWS
2024 Acid Maltase Deficiency Association (AMDA)/International Pompe Association (IPA) Conference date has been set!
Dear Pompe Warriors and Patient Community, We are excited to announce the upcoming 2024 Acid Maltase Deficiency Associate - International Pompe Association (AMDA-IPA) Conference, a momentous event dedicated to advancing knowledge, support, and advocacy for individuals...
Rare Artist Contest is now Open for Submissions
Enter July 23rd - August 31st at RareArtist.org The Rare Artist Program was established in 2010 to exhibit the unique gifts of individuals impacted by rare disease to tell their story through art. Now in year 13, the Rare Artist Annual Contest is focused on providing...
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
PHILADELPHIA, June 27, 2023 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, today announced that the European Commission (EC) has...
2023 PCMA Pull for Pompe Fundraiser
The AMDA is excited to announce that the 12th Annual PCMA’s Pull for Pompe will take place on Saturday, April 29, 2023 at the National Shooting Complex in San Antonio, Texas! The Pull for Pompe clay shooting event is designed for all ages and ability levels. Please...
2022 Helen Walker Research Grant For Pompe Disease Now Accepting Appliations
The AMDA is excited to announce a research grant opportunity for applicants who are involved in Pompe Disease research. This grant opportunity was made possible by the 2022 Pull for Pompe, a private fundraiser held by the Precast Manufacturer's Association of Texas...
An Open Letter to the Pompe Community
On October 28, Amicus Therapeutics issued a press release with an update on the progress of our Pompe program as we received information from the US Food & Drug Administration (FDA) on the regulatory status of our next-generation therapy for the treatment of...
International Survey on Pompe Disease and Covid-19
Over the last 2 years the COVID-19 pandemic has had wide reaching effects on people all over the world. To better understand the impact of the Covid 19 Pandemic on the worldwide Pompe community, the International Pompe Association and the Erasmus MC are undertaking a...
2021 Helen Walker Grant for Pompe Disease Winner Announcement
The AMDA is excited to announce that the 2021 Helen Walker Grant for Pompe Disease was awarded to Dr. Peter Meinke and Dr. Benedikt Schoser for their Project entitled: "Generation of a platform for comparative testing of new treatments for people living with Pompe...
Astellas Gene Therapies Press Release – Clinical Trial Update
"On June 26, 2022, Astellas Pharma, Inc. ("Astellas") issued a press release announcing that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the FORTIS Phase 1/2 clinical trial evaluating AT845 ("the investigational gene therapy candidate")...
Voice of the Patient Report for the Pompe PFDD is Released!
The AMDA is excited to report that the final Voice of the Patient Report for the Pompe Patient-Focused Drug Development meeting has been released. To view the report, please CLICK HERE!
Acid Maltase Deficiency Association
For the AMDA videos: All Rights reserved. No part of the AMDA's videos may be reproduced or transmitted in any form or by any means, electronic or mechanical, without the written permission of the copyright holder.
If you are interested in learning more about Pompe Disease and would like to make a contribution in support of necessary research, please contact us at:
info@amda-pompe.org
THE AMDA
PO Box 700248
San Antonio, Texas 78270 USA